NCT07200986 - Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects | Biotech Hunter

Enrollment

218

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Healthy Participants

Interventions

BIOLOGICAL

Ixekizumab

80 mg (single dose), SC injection via PFS

Trial Locations (5)

RECRUITING

Inje University Busan Paik Hospital, Busan

RECRUITING

CHA Bundang Medical Center, Seongnam-si

ACTIVE_NOT_RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

RECRUITING

Chungbuk National University Hospital, Cheongju-si

RECRUITING

Seoul National University Hospital, Seoul